Congenital erythropoietic porphyria: skeletal manifestations and effect of pamidronate treatment.
Congenital erythropoietic porphyria (CEP) is a rare disorder of heme biosynthesis. Skeletal abnormalities have been described in patients with this disease. We report a 25-year-old woman with osteodystrophy from CEP. On examination, mild hepatosplenomegaly, multiple hyperpigmented scars, hypertrichosis, erythrodontia and red coloration of urine were found. Biochemical studies showed increased serum levels of alkaline phosphatase, fasting and total 24-h urinary calcium excretion. Serum 250H vitamin-D concentration was low due to avoidance of sun exposure. Skeletal radiographs disclosed marked vertical and horizontal trabecular pattern and biconcavity of most of the dorsal and lumbar vertebral bodies. Several round sclerotic lesions (1-3 cm in diameter) were seen in the skull, pelvis and one lumbar vertebrae. The sclerotic lesions were augmented in size and number compared to X-rays obtained 8 years before. Bone mineral density (evaluated by DEXA) was markedly reduced at the spine and moderately diminished at the proximal femur and total skeleton. Treatment for 11 months with pamidronate (and the addition of hydrochlorotiazide for the last 6 months) reduced to normal values the serum levels of alkaline phosphatase and fasting urinary calcium. The 24-h urinary excretion of calcium and hydroxyproline were also decreased. The BMD increased in all the skeletal areas with presumably hyperactive bone marrow: spine, head, ribs and pelvis (and total skeleton), but did not change at the extremities and diminished at the femoral neck. Patients with CEP may present osteodystrophy characterized by sclerotic lesions and osteopenia, most likely due to accelerated bone turnover in areas of active bone marrow.(ABSTRACT TRUNCATED AT 250 WORDS)
Sección Osteopatías Médicas, Hospital de Clínicas, Universidad de Buenos Aires, Argentina.
M B
MB
Oliveri
C
C
Mautalen
M
M
Mega
E
E
Rossi
D000328:Adult; D015519:Bone Density / Q000187:drug effects; D002118:Calcium / Q000652:urine; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D010014:Osteolysis / Q000188:drug therapy* / Q000209:etiology / Q000652:urine; D010022:Osteopetrosis / Q000188:drug therapy* / Q000209:etiology / Q000652:urine; D000077268:Pamidronate; D017092:Porphyria, Erythropoietic / Q000150:complications* / Q000652:urine; D013131:Spine / Q000187:drug effects
D004164:Diphosphonates; D000077268:Pamidronate; D002118:Calcium